All In Biotech

Drug Trial Radar · NCT05712694

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

218

Actual

Start

Nov 29, 2023

Primary completion

May 25, 2026

Study completion May 25, 2026

Sponsor

Lead sponsor
Polaris GroupIndustry
Sponsor type
Industry
First posted
Feb 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • ADI PEG20Drug

    Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

  • PlaceboOther

    Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary End Point of PFSTime frame: Subjects will receive triplet combination treatment followed by weekly monotherapy ADI-PEG 20 or PBO (Each cycle is 21 days). Subjects tolerating chemotherapy may continue chemotherapy beyond 8 cycles and up to 104 weeks (~2 years).

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • USC Norris comprehensive cancer center

    Los Angeles, California

  • Stanford University Medical Centre

    Palo Alto, California

  • UCSF

    San Francisco, California

  • UCLA

    Santa Monica, California

  • University of Colorado Cancer Center/ CU Anschutz Medical Campus

    Aurora, Colorado

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami/ Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Mass General Brigham Cancer Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • NYU Langone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center/ The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • UPenn (Abramson Cancer Center, Pennsylvania Hospital)

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Medical College of Wisconsin/ Froedtert Hospital

    Milwaukee, Wisconsin

  • UHN - Princess Margaret Cancer Center (Ontario)

    Toronto, Ontario, Canada

  • McGill University Health Centre (Quebec)

    Montreal, Quebec, Canada

  • Chang Gung Medical Foundation Kaohsiung

    Kaohsiung City, Niaosong District, Taiwan

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.